ABC | Volume 115, Nº1, July 2020

Original Article Macedo et al. Resistant hypertension in afrodescendants Arq Bras Cardiol. 2020; 115(1):31-39 17. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH, et al. Management of high blood pressure in blacks: An update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56(5):780–800. 18. Lotufo PA, Pereira AC, Vasconcellos PS, Santos IS, Mill JG, Bensenor IM. Resistant hypertension: Risk factors, subclinical atherosclerosis, and comorbidities among adults-the brazilian longitudinal study of adult health (ELSA-Brasil). J Clin Hypertens. 2015;17(1):74–80. 19. Boolani H, Sinha A, Randall O. Resistant Hypertension. Curr Cardiovasc Risk Rep. 2013;7(5):354–63. 20. Mente A, O’Donnell MJ, Rangarajan S, McQueenMJ, Poirier P, Wielgosz A, et al. Association of Urinary Sodium and Potassium Excretion with Blood Pressure. N Engl J Med. 2014;371(7):601–11. 21. Grim CE, Grim CM. Omron HEM-711 DLX home Blood pressure monitor passes the European Society of Hypertension International Validation Protocol. Blood Press Monit. 2008 Aug;13(4):225–6. 22. Vera-Cala LM, Orostegui M, Valencia-Angel LI, López N, Bautista LE. Precisão do Aparelho Omron HEM-705 CP na Medida de Pressão Arterial emGrandes Estudos Epidemiológicos. Arq Bras Cardiol. 2011;96(5):393–8. 23. Cockcroft DW& Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. 24. Napoli Filho MDi, Burmeister JE, Miltersteiner R, Machado B, Generali M. Estimativa da Função Renal pela Fórmula de Cockcroft eGault emPacientes com Sobrepeso ou com Obesidade Estimation of Renal Function by the Cockcroft and Gault Formula in Overweighted or Obese Patients. J Bras Nefrol. 2008;30(3):185–91. 25. Oliveira-Filho AD, Barreto-Filho JA, Neves SJF, Lyra Junior DP de. Relação entre a Escala de Adesão Terapêutica de oito itens de Morisky (MMAS-8) e o controle da pressão arterial. Arq Bras Cardiol. 2012;99(1):649–58. 26. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive Validity of A Madication AdherenceMeasure in anOutpatient Setting. J ClinHypertens. 2008;10(5):348–54. 27. Dudenbostel T, Siddiqui M, Gharpure N, Calhoun DA. Refractory versus resistanthy pertension:Noveldistinctivephenotypes.JNatSci. 2017;3(9):1–6. 28. CushmanWC, Ford CE, Cutler J a, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393–404. 29. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42. 30. Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension. 2014;64(5):1012–21. 31. Holmqvist L, BoströmKB, Kahan T, Schiöler L, Hasselström J, Hjerpe P, et al. Prevalence of treatment-resistant hypertension and important associated factors—results from the Swedish Primary Care Cardiovascular Database. J Am Soc Hypertens. 2016;10(11):838–46. 32. De La Sierra A, Segura J, Banegas JR, Gorostidi M, De La Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898–902. 33. Václavík J, Sedlák R, PlachýM, Navrátil K, Plášek J, Jarkovský J, et al. Addition ofspironolactone inpatientswithresistantarterialhypertension (ASPIRANT): A randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069–75. 34. Williams B, Macdonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–68. 35. Grassi G, Bombelli M, Seravalle G, Brambilla G, Dell’Oro R, Mancia G. Role of ambulatory blood pressure monitoring in resistant hypertension. Curr Hypertens Rep. 2013;15(3):232–7. 36. Irvin MR, Booth JN, Shimbo D, Lackland DT, Oparil S, Howard G, et al. Apparenttreatment-resistanthypertensionandrisk forstroke,coronaryheart disease, and all-cause mortality. J Am Soc Hypertens. 2014;8(6):405–13. 37. de Beus E, van der Sande NGC, Bots ML, Spiering W, Voskuil M, Visseren FLJ, et al. Prevalence and clinical characteristics of apparent therapy-resistant hypertension inpatientswithcardiovasculardisease:across-sectionalcohort study in secondary care. BMJ Open. 2017;7(9):e016692. 38. Baldo MP, Cunha RS, Ribeiro ALP, Lotufo PA, Chor D, Barreto SM, et al. Racial Differences in Arterial Stiffness are Mainly Determined by Blood Pressure Levels: Results From the ELSA – Brasil Study. J Am Heart Assoc. 2017;6(6):e005477. 38